ICD-10-PCS 2027 procedure code
XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
Short description: Introduce Brexucab in Periph Vein, Perc, New Tech 7
Code last changed in FY2022 (effective October 1, 2021). Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data
About XW033M7
XW033M7 is the ICD-10-PCS code for a introduction procedure on the peripheral vein using a percutaneous approach with brexucabtagene autoleucel immunotherapy (qualifier: new technology group 7). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
For a different body part, codes include XW043M7 (central vein).
With a different device, use XW03357 (ifezuntirgene inilparvovec), XW033A7 (ciltacabtagene autoleucel), XW033C7 (recombinant human bone morphogenetic protein-2 with collagen scaffold), XW033G7 (vancomycin hydrochloride and tobramycin sulfate anti-infective, temporary irrigation spacer system), XW033H7 (paclitaxel-coated balloon technology, one balloon), XW033J7 (paclitaxel-coated balloon technology, two balloons) and 3 more.
It is a non-O.R. procedure that is part of the MS-DRG logic for DRG 018 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies), under the surgical category “Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies”.
It was added in FY2022, effective October 1, 2021.
What each character means
- 1. Section
- XNew Technology
- 2. Body System
- WAnatomical Regions
- 3. Operation
- 0Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
- 4. Body Part
- 3Peripheral Vein
- 5. Approach
- 3Percutaneous
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
- 6. Device / Substance / Technology
- MBrexucabtagene Autoleucel Immunotherapy
Includes: Brexucabtagene Autoleucel; Tecartus(tm)
- 7. Qualifier
- 7New Technology Group 7
Other versions of this procedure
Different body part
Different device / substance / technology
- XW03357Ifezuntirgene Inilparvovec
- XW033A7Ciltacabtagene Autoleucel
- XW033C7Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold
- XW033G7Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System
- XW033H7Paclitaxel-Coated Balloon Technology, One Balloon
- XW033J7Paclitaxel-Coated Balloon Technology, Two Balloons
- XW033K7Paclitaxel-Coated Balloon Technology, Three Balloons
- XW033L7Paclitaxel-Coated Balloon Technology, Four or More Balloons
- XW033N7SER-109
Different qualifier
MS-DRG v44.0 grouping
All DRGs →Surgical MS-DRGs this procedure can group to, depending on the principal diagnosis's MDC.
MDC PRE · Pre-MDC · Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2022 (effective 10/1/2021): Added
- No changes since FY2022.
Common questions about XW033M7
Is XW033M7 a valid ICD-10-PCS code for 2027?
- Yes. XW033M7 is valid for inpatient procedures from October 1, 2026 through September 30, 2027.
Is XW033M7 an O.R. procedure?
- No. XW033M7 is designated non-O.R. in MS-DRG v44.0.
What DRG does XW033M7 group to?
- Depending on the principal diagnosis, XW033M7 can group to MS-DRG 018.